Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK

Fig. 3

Role of the PI3-Delta isoform in melanoma cell growth. a Melanoma cells were seeded in 96-well plates (5000 cells/well) and treated 24 h later with inhibitors of IC87114. b Response to IC87114 in lines with high and low expression levels of PIK3-Delta isoform. c Response to IC87114 in lines with PIK3CA variants. d Response to IC87114 in lines with PIK3R1 variants. BRAF: BRAF-mutant cell lines; RAS: RAS-mutant cell lines; other: cell lines wild-type for both BRAF and RAS. Data were from 2 to 4 independent experiments performed in duplicates. Yellow areas represent the concentration ranges between the biochemical IC50 and 100 x IC50 values of inhibitors for their specific targets; x-axis represents cell-based EC50 values; y-axis represents inhibition % at 100 μM of the corresponding inhibitors where 100% inhibition indicates complete stop of cell growth

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us